CTI BioPharma Corp. (NASDAQ:CTIC) most recently reported quarterly actual earnings per share of $-0.07 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-0.09. The difference between the estimate and the actual EPS was $0.02 creating a surprise factor of 22.22%. Currently, the company has an impact score of 0. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $0.75 on the shares. The most bullish brokerage firm has a $0.75 target, while the most bearish sees the stock headed towards $0.75. This is according to the 1 estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 3.67. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 1 recommendations taking into account in order to arrive at this number. Of the 1, 0 have a Strong Buy rating and 0 are rating it a Buy.

Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial of pacritinib for the treatment of myelofibrosis. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects.

CTI BioPharma Corp. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.